Opinion & analysis

The Gene Therapies Are Coming – And So Are New Ways To Pay For Them

At the 2019 J.P. Morgan Healthcare Conference, bluebird bio Inc. became the first company to propose a 5-year annual installment payment plan for its gene therapy Lentiglobin, the first such payment plan proposal of its kind. Hear more about the reaction to the proposal from other pharma players and from insurers in this informative Scrip article.

Get a more in-depth analysis on Pharmaceutical market trends with our Opinion on Analysis reports.

The Gene Therapies Are Coming – And So Are New Ways To Pay For Them

CMS Actively Looking For New Reimbursement Pathway For Innovative Devices

UK Notified Body BSI Sets Out Clear Post-Brexit Paths As It Goes Dutch

DECIEM, Truly ‘The Abnormal Beauty Company,’ Faces Uncertain Future

What Do Cosmetics Reform Campaigners Dream Of At Night? Rep. Schakowsky Just Reintroduced It

Takeda To Press On With Core R&D Strategy Post-Shire

86% Rise In GMDN Usage Heralds New Era Of Postmarket Data Analytics

Ranitidine Recalls Begin In Europe As Regulators Take Action

Top 10 Drugs: Biologic Blockbusters And The Biosimilar Threat

FDA Ban On Flavoring Ingredients Should Prompt Removal From Fragrances – WVE

Abbott Launches New App To Keep Heart Failure Patients Out Of The Hospital

Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions

EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses

Interventional Cardiology: Implantable Cardioverter Defibrillators

In Vivo’s Quick Guide To Gene Therapy

Colgate/Tom’s Of Maine Pays Back Unilever For ‘Naturally Dry’ Loss

As Humira Biosimilars Arrive, Battle Lines Shift From Education To Sustainability

Innovations In Market Access: The Will, But Not The Way?

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Novartis’ New Oncology CEO Liz Barrett Charts A Course, But It Will Require Jump-Starting New Brands

2018 Completed Clinical Trials: Change Is The New Constant

Novartis’s Zolgensma Loses EU Accelerated Assessment

116th Congress Could Test Cosmetic Industry’s Commitment To Reg Reform, Preemption Viability

2018’s Top Biopharma Deal-makers

Interventional Neurology: Cerebral Aneurysm and Arteriovenous Malformation Systems

Contamination In Common OTC Antacid Adds To FDA’s API Impurity Concerns

Burt’s Bees Hopes Third Time’s A Charm For Toothpaste, This One With P&G

US FDA’s Temple on Real-world Evidence: “I Find the Whole Thing Very Frustrating”

Into 2019: Risk, Uncertainty And A Return To Product Focus

Orphan Drug Pricing And Reimbursement: Challenges To Patient Access